Physician profile
Steven Tabak
NPI 1124090576
$5,510.78
in general payments reported to CMS, 2019-2025
23 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $74.41 · 2021: $47.95 · 2022: $407 · 2023: $3,363 · 2024: $265 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Food and Beverage | $1,228.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,016.00 | 2023 | Ion, Da Vinci Surgical System |
| Amgen INC. | $662.43 | 2019-2024 | Repatha |
| Boston Scientific Corporation | $226.03 | 2019 | |
| Medtronic, INC. | $221.93 | 2025 | Affera Mapping System, Endurant Iis |
| Novartis Pharmaceuticals Corporation | $205.66 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $181.03 | 2019-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $149.59 | 2019 | |
| Biosense Webster, INC. | $108.58 | 2022 | |
| Pfizer INC. | $105.76 | 2023-2025 | |
| Heartflow, INC. | $93.02 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $90.44 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $75.43 | 2023-2025 | Wainua, Farxiga |
| Gilead Sciences, INC. | $49.47 | 2019 | |
| Scpharmaceuticals INC. | $49.25 | 2023-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $44.35 | 2024 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $36.46 | 2022 | |
| Abiomed | $36.44 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $29.87 | 2023 | Inpefa |
| Bridgebio Pharma, INC. | $29.74 | 2025 | Attruby |
| Esperion Therapeutics, INC. | $28.13 | 2020 | |
| Novo Nordisk INC | $24.93 | 2024 | Ozempic |
| Edwards Lifesciences Corporation | $24.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.71 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Tabak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.